Can AI Run Your Regulatory CMC Program?

Find Out Here!

The pharmaceutical industry is entering a new era where Artificial Intelligence is no longer just helping teams work faster. It is beginning to shape how development programs are planned, executed, reviewed, and even defended.

But here is the real question: Can AI actually run your Regulatory CMC program? The answer is both yes and no.

AI can absolutely transform large portions of Regulatory CMC operations. In some organizations, it already is. But the companies expecting AI to simply “replace the CMC team” are misunderstanding what makes successful development programs work in the first place.

The future is not human versus AI. The future is hybrid intelligence.

The Traditional CMC Problem

Most Regulatory CMC programs are still built around fragmented systems, disconnected vendors, manual document creation, and reactive decision making.

Critical development knowledge lives everywhere:

• Batch records
• Stability reports
• Analytical methods
• Deviation investigations
• Tech transfer documents
• Email chains
• CDMO meeting notes
• Regulatory commitments
• Validation protocols
• Development reports

Then comes the impossible task:

Turn thousands of pages of evolving technical data into a coherent regulatory strategy and submission narrative.

That process is still heavily manual across much of the industry.

And it creates enormous risk.

Not because teams are inexperienced.

Because humans simply cannot continuously connect every relationship, dependency, commitment, and regulatory expectation across a rapidly evolving program without technological augmentation.

What AI Can Already Do Today

Modern AI systems are now capable of…

Building First-Pass Module 3 Content

AI can analyze structured and unstructured CMC data and generate large portions of:

• Drug Substance sections
• Drug Product sections
• Analytical summaries
• Stability narratives
• Process descriptions
• Control strategies
• Comparability discussions
• Quality Overall Summary content

What previously took hundreds of authoring hours can now be developed in a fraction of the time.

AI Can Identify Gaps Before FDA Does

One of the most powerful capabilities emerging today is AI-driven gap detection.

AI systems can compare your evolving program against:

• ICH expectations
• FDA precedents
• Internal strategies
• Prior commitments
• Phase-appropriate expectations
• Lifecycle requirements

This allows teams to identify inconsistencies early, including:

• Missing justification logic
• Weak specification rationale
• Incomplete analytical support
• Stability gaps
• Inconsistent control strategies
• Data conflicts between sections

In many cases, AI can detect regulatory weaknesses long before a traditional manual review cycle would uncover them.

AI Is Becoming Agentic

The next wave is even more important. AI is no longer limited to answering questions.

Agentic AI systems are now being configured to:

• Gather required data automatically
• Trigger workflows
• Identify missing reports
• Request supporting information
• Assemble submission-ready packages
• Track commitments across development phases
• Prepare health authority response drafts
• Monitor development readiness in real time

This changes AI from a passive tool into an operational decision-support layer.

Instead of waiting for humans to ask questions, the system begins identifying what it needs to support the strategy itself. That is where the industry is heading.

But AI Alone Is Not Enough

This is where many companies get it wrong.

Regulatory CMC is not simply a writing exercise.

It is strategic risk management.

FDA reviewers do not approve documents because they are polished.

They approve programs because the development story makes scientific and regulatory sense.

AI can organize data.

AI can draft content.

AI can identify patterns.

But experienced Regulatory CMC leadership still determines:

• What risks matter
• Which strategy is defendable
• How to position deviations
• When to justify versus remediate
• How aggressive a control strategy should be
• What the agency is most likely to challenge
• How lifecycle decisions affect future approvals

That requires judgment developed through years of real-world program experience.

The Winning Model: Hybrid Regulatory Intelligence

The companies that will dominate the next decade will not be the ones replacing people with AI.

They will be the ones augmenting expert teams with intelligent systems.

At Enkrisi, this is exactly why we developed EnkrisiGPT.

Not simply to draft submissions.

But to help drive the entire Regulatory CMC process:

• Building strategy
• Identifying risks
• Gathering supporting data
• Authoring Module 3 and QOS content
• Supporting lifecycle management
• Maintaining consistency across evolving programs

The goal is not automation for the sake of automation.

The goal is reducing risk while accelerating development.

So… Can AI Run Your Regulatory CMC Program?

If by “run” you mean:

• Organize information?
• Build first-pass submissions?
• Detect gaps?
• Coordinate workflows?
• Support decision making?
• Reduce manual burden?
• Improve consistency?

Then yes.

It already can.

But if you mean replacing experienced Regulatory CMC leadership entirely?

Not even close.

The future belongs to organizations combining:

• Deep CMC expertise
• Structured data systems
• Agentic AI workflows
• Intelligent authoring
• Strategic regulatory oversight

That combination will fundamentally change how drug development programs are executed over the next five years.

And many companies are not prepared for how fast this transition is coming.